BioTime's Research to be Presented at Berkeley Conference on Aging.Business Editors & Health/Medical Writers BIOWIRE2K BERKELEY, Calif.--(BW HealthWire)--Oct. 1, 2001 BioTime, Inc. (AMEX AMEX See: American Stock Exchange :BTX (Balanced Technology EXtended) A motherboard design from Intel introduced in 2004 that supersedes the ATX. Unlike the ATX, the placement of all chip sockets in the BTX is defined in order to provide sufficient air flow over the processor and display adapter. ) announced today that it will be presenting research on low temperature medicine, resuscitation resuscitation /re·sus·ci·ta·tion/ (-sus?i-ta´shun) restoration to life of one apparently dead. cardiopulmonary resuscitation , hyperbaric medicine, and interventive gerontology gerontology: see geriatrics. at the upcoming conference sponsored by the Center For Research and Education in Aging (CREA CREA Creative CREA Creatine CREA Canadian Real Estate Association CREA Conselho Regional de Engenharia, Arquitetura E Agronomia (Regional Engineering, Architecture and Agronomy Council - Brazil) ) at the University of California at Berkeley (body, education) University of California at Berkeley - (UCB) See also Berzerkley, BSD. http://berkeley.edu/. Note to British and Commonwealth readers: that's /berk'lee/, not /bark'lee/ as in British Received Pronunciation. scheduled for October 20, 2001. BioTime will present studies using its proprietary solutions in laboratory models of low temperature cardiac surgery and trauma care, organ and tissue preservation, hyperbaric oxygen therapy Hyperbaric oxygen therapy (HBO) A treatment in which the patient is placed in a chamber and breathes oxygen at higher-than-atmospheric pressure. This high-pressure oxygen stops bacteria from growing and, at high enough pressure, kills them. , and the treatment of hypovolemia hypovolemia /hy·po·vo·le·mia/ (-vol-em´e-ah) diminished volume of circulating blood in the body.hypovole´mic hy·po·vo·le·mi·a n. See oligemia. (low blood volume). It will also present immunohistochemical and computerized cell scanning methods designed to better understand age-related brain pathology. "We expect that the development of these exciting technologies will allow us to broaden the BioTime product line with a number of new products for the medical market place," said Dr. Paul Segall, BioTime chairman and chief executive officer. "To reach this goal, we have a comprehensive product development plan to couple our own in-house efforts with research conducted through collaborations with other pharmaceutical companies, medical centers, universities, and the military. This program is advancing while sales of BioTime's proprietary plasma volume expander, now used in hundreds of leading hospitals around the country, gain momentum." BioTime, headquartered in Berkeley, California develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Information about BioTime can be found on the web at www.biotimeinc.com. The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of BioTime products; BioTime's ability to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and foreign regulatory approval to market its products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime's products; BioTime's ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in BioTime products; the availability of reimbursement for the cost of BioTime products (and related treatment) from government health administration authorities, private health coverage insurers and other organizations; and the ability of BioTime to raise additional capital. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion